Astex Pharmaceuticals Inc., of Dublin, Calif., said that its HSP90 inhibitor, AT13387, showed activity in in vitro gastrointestinal stromal tumor (GIST) models. The compound was more active than 17-AAG, a first-generation HSP90 inhibitor, in all cell lines tested.